|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
gptkb:anti-angiogenic_drug
|
|
gptkbp:administeredBy
|
gptkb:physician
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2004
|
|
gptkbp:ATCCode
|
L01XC07
|
|
gptkbp:biosimilar
|
gptkb:Alymsys
gptkb:Mvasi
gptkb:Zirabev
Aybintio
|
|
gptkbp:brand
|
gptkb:Avastin
|
|
gptkbp:CASNumber
|
216974-75-3
|
|
gptkbp:chemicalFormula
|
C6638H10160N1720O2104S44
|
|
gptkbp:contraindication
|
uncontrolled hypertension
hypersensitivity to bevacizumab
recent surgery
|
|
gptkbp:cost
|
high
|
|
gptkbp:developedBy
|
gptkb:Genentech
|
|
gptkbp:eliminationHalfLife
|
20 days
|
|
gptkbp:KEGGID
|
D04139
|
|
gptkbp:legalStatus
|
prescription only
expired in US
|
|
gptkbp:marketedAs
|
gptkb:Roche
|
|
gptkbp:mechanismOfAction
|
inhibits VEGF-A
|
|
gptkbp:MedlinePlusID
|
a607001
|
|
gptkbp:molecularWeight
|
149 kDa
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
DB00112
24859646
CHEMBL1201588
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
bleeding
hypertension
proteinuria
gastrointestinal perforation
impaired wound healing
|
|
gptkbp:target
|
gptkb:VEGF-A
|
|
gptkbp:type
|
humanized monoclonal antibody
|
|
gptkbp:UNII
|
82S8T18449
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
gptkb:age-related_macular_degeneration
gptkb:cancer
gptkb:renal_cell_carcinoma
gptkb:fallopian_tube_cancer
gptkb:glioblastoma
colorectal cancer
peritoneal cancer
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bevacizumab
|